People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Pharmaceuticals, Other Health Care, Other Technology, Other, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tribute Pharmaceuticals Canada Inc. | — | Pharmaceuticals | Series C | $92.1M | $2.6B | 2013 |
| Metropolitan Detroit Area Hospital Services, Inc. | — | Other Health Care | Series C | $47.1M | $1.1B | 2019 |
| Pontiflex Inc | — | Other Technology | Series A | $27.0M | $34.7M | 2011 |
| Dispersive Holdings, Inc. | — | Other | Series A | $9.6M | $22.4M | 2021 |
| Amarantus Bioscience Holdings, Inc. | — | Pharmaceuticals | Seed | $6.0M | $11.4M | 2014 |
| Torchlite Technologies Inc. | — | Software / Tech | Seed | $4.3M | $8.3M | 2021 |
| Clutch! LLC | — | Other Technology | Pre-Seed | $683K | $28.9M | 2018 |
| Spark Motion, Inc. | — | Other Technology | Pre-Seed | $400K | $12.7M | 2012 |
| Priority Endeavors, LLC | — | Other Technology | Pre-Seed | $100K | $4.2M | 2015 |
Robert Harris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Harris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert L. Harris | 2 | 4 |
| Brian Hirsch | 1 | 19 |
| Eric Wiesen | 1 | 17 |
| Scott Johnson | 1 | 10 |
| James O' Connor | 1 | 10 |
| PAUL SCHAUT | 1 | 6 |
| William Porteous | 1 | 6 |
| David Lowe | 1 | 5 |
| Andrew I. Koven | 1 | 4 |
| Eric L. Trachtenberg | 1 | 4 |
| David Knight | 1 | 4 |
| Robert Farrell | 1 | 4 |
| Scott McCorkle | 1 | 4 |
| Scott Harris | 1 | 4 |
| Tiffany McCorkle | 1 | 3 |
| Kelly Schwedland | 1 | 3 |
| Scott Eisenberg | 1 | 3 |
| ZEPHRIN LASKER | 1 | 2 |
| James Continenza | 1 | 2 |
| Steven H Goldman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.